- published: 08 Dec 2021
- views: 1559
-
remove the playlistAction For Research Into Multiple Sclerosis
- remove the playlistAction For Research Into Multiple Sclerosis
Multiple sclerosis
Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often occur, especially as the disease advances.
While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as infections. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.
This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/Multiple_sclerosis
Podcasts:
-
Research in Multiple Sclerosis | Webinar
Board Chair David W. Dodick, MD, FAAN hosted an informative discussion with Scientific Advisory Board Member Raymond Roos, MD, FAAN, about research in multiple sclerosis and what’s giving hope to those living with the disease. They discussed what is currently known about multiple sclerosis and what we need to learn to improve diagnosis and treatment. Audience members also had a chance to ask questions related to risk factors, modifying therapies, and research developments for multiple sclerosis. For more information and resources visit our website at https://www.americanbrainfoundation.org/ Join our community: Facebook: https://www.facebook.com/AmericanBrainFoundation/ Instagram: https://www.instagram.com/americanbrainfoundation/ Twitter: https://twitter.com/abfbrain LinkedIn: https:/...
published: 08 Dec 2021 -
Research in MS: Can the Course be Modified? 2012 - by Patrizia Casaccia, MD
Presented at Changing the Future: New Trends in MS and Research, held at the Grand Hyatt NYC on Sunday 11/4/2012 Brought to you by the CGD Center for MS at The Mount Sinai Medical Center. http://www.mountsinai.org/mscenter
published: 12 Feb 2013 -
Frexalimab in Multiple Sclerosis | NEJM
For patients with relapsing multiple sclerosis, inhibition of CD40L with the monoclonal antibody frexalimab may be a viable therapeutic strategy. Research findings are summarized in a new Quick Take video. To see the full article, follow this link: https://nej.md/4bExZHa
published: 15 Feb 2024 -
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
Previously, Bruton's tyrosine kinase inhibitors (BTKis) have primarily been used for the treatment of B-cell cancers to deplete B-cell proliferation. BTKis are currently being investigated as a novel disease modifying therapy for the treatment of MS. Rochelle Benoit, MS, Memorial University of Newfoundland, St. John's, Newfoundland, Canada, discusses the use of BTKis in MS and investigations into their impact in non-B cell populations, including monocytes, macrophages, and microglia. When human-derived macrophages were treated with evobrutinib and tolebrutinib, a significant decrease in proinflammatory cytokine release was observed. The same effect was not seen in mouse-derived macrophages, suggesting a possible species difference in the cellular role of BTKs. This interview took place at ...
published: 23 Mar 2022 -
Intelligent Intervention Into Multiple Sclerosis With Next-Generation Therapies
As scientists learn more about the underlying causes of multiple sclerosis (MS), they are developing intelligent interventions that slow or halt the progression of the disease. In this Front Row lecture, Scripps Research Professor Hugh Rosen will share how he and his collaborators at Scripps Research created ozanimod (Zeposia), the first disease-altering MS therapy, recently approved in the United States and Europe. Luke Lairson, an associate professor at Scripps Research, will discuss how his research targeting another aspect of the disease is laying the groundwork for the next generation of MS therapies. Presented: July 1, 2020 https://www.scripps.edu Register for future Front Row lectures: https://frontrow.scripps.edu/
published: 02 Jul 2020 -
Future studies on aHSCT for multiple sclerosis
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and future studies to improve the use of autologous hematopoietic stem cell transplantation (aHSCT) for the treatment of multiple sclerosis (MS). A clinical trial comparing aHSCT versus the best available therapy is ongoing, and its results are highly awaited. Studies investigating the long-term survival after aHSCT will provide important data about the potential of aHSCT to avoid the switch to the progressive phase of the disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the ...
published: 20 Dec 2022 -
Nestorone for multiple sclerosis
Nestorone, created by the Population Council Center for Biomedical Research, has the potential to help remyelinate axons damaged as a result of Multiple Sclerosis. ━━━━━━━━━━━━━━━━━━━━ Additional Information ──────────────────────────── https://www.popcouncil.org/cbr ━━━━━━━━━━━━━━━━━━━━ Science Animated ──────────────────────────── http://www.sciani.com/ https://twitter.com/Sci_Ani https://www.facebook.com/scianimation/ ━━━━━━━━━━━━━━━━━━━━ #Nestorone #MultipleSclerosis #MS ━━━━━━━━━━━━━━━━━━━━
published: 29 Sep 2020 -
Role of Ozanimod in Multiple Sclerosis
Sven Meuth, MD, PhD, describes the phase 3 clinical trials SUNBEAM and RADIANCE of ozanimod for multiple sclerosis.
published: 25 Aug 2020 -
Unveil the hidden truth: Milk sabotages remyelination
Milk, often portrayed as a staple of health, harbors a dark side. Disguised within those innocent glasses lies a concoction of proteins that can incite inflammation, hindering the miraculous process of remyelination. In this dairy dilemma, the choice to transition to a dairy-free, vegan lifestyle emerges not just as a dietary shift but as a transformative step towards fostering remyelination and embracing a path of healing and empowerment. The story of remyelination transcends mere physical recovery; it symbolizes a journey of resilience, hope, and the profound impact of conscious dietary choices on one's health and vitality. Through the prism of remyelination, the narrative evolves into a tale of transformation, illustrating the potential for healing and wholeness through mindful decisi...
published: 24 Jun 2024 -
New Studies Help Momentum Move Forward in Multiple Sclerosis Care
There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, and very early signs of hope for secondary progressive. As a result there was plenty of optimism at ECTRIMS as it left London and prepared for Paris next year.
published: 20 Sep 2016
developed with YouTube
55:58
Research in Multiple Sclerosis | Webinar
- Order: Reorder
- Duration: 55:58
- Uploaded Date: 08 Dec 2021
- views: 1559
Board Chair David W. Dodick, MD, FAAN hosted an informative discussion with Scientific Advisory Board Member Raymond Roos, MD, FAAN, about research in multiple ...
Board Chair David W. Dodick, MD, FAAN hosted an informative discussion with Scientific Advisory Board Member Raymond Roos, MD, FAAN, about research in multiple sclerosis and what’s giving hope to those living with the disease. They discussed what is currently known about multiple sclerosis and what we need to learn to improve diagnosis and treatment. Audience members also had a chance to ask questions related to risk factors, modifying therapies, and research developments for multiple sclerosis.
For more information and resources visit our website at https://www.americanbrainfoundation.org/
Join our community:
Facebook: https://www.facebook.com/AmericanBrainFoundation/
Instagram: https://www.instagram.com/americanbrainfoundation/
Twitter: https://twitter.com/abfbrain
LinkedIn: https://www.linkedin.com/company/american-brain-foundation/
https://wn.com/Research_In_Multiple_Sclerosis_|_Webinar
Board Chair David W. Dodick, MD, FAAN hosted an informative discussion with Scientific Advisory Board Member Raymond Roos, MD, FAAN, about research in multiple sclerosis and what’s giving hope to those living with the disease. They discussed what is currently known about multiple sclerosis and what we need to learn to improve diagnosis and treatment. Audience members also had a chance to ask questions related to risk factors, modifying therapies, and research developments for multiple sclerosis.
For more information and resources visit our website at https://www.americanbrainfoundation.org/
Join our community:
Facebook: https://www.facebook.com/AmericanBrainFoundation/
Instagram: https://www.instagram.com/americanbrainfoundation/
Twitter: https://twitter.com/abfbrain
LinkedIn: https://www.linkedin.com/company/american-brain-foundation/
24:46
Research in MS: Can the Course be Modified? 2012 - by Patrizia Casaccia, MD
- Order: Reorder
- Duration: 24:46
- Uploaded Date: 12 Feb 2013
- views: 1326
Presented at Changing the Future: New Trends in MS and Research, held at the Grand Hyatt NYC on Sunday 11/4/2012
Brought to you by the CGD Center for MS at The...
Presented at Changing the Future: New Trends in MS and Research, held at the Grand Hyatt NYC on Sunday 11/4/2012
Brought to you by the CGD Center for MS at The Mount Sinai Medical Center.
http://www.mountsinai.org/mscenter
https://wn.com/Research_In_Ms_Can_The_Course_Be_Modified_2012_By_Patrizia_Casaccia,_Md
Presented at Changing the Future: New Trends in MS and Research, held at the Grand Hyatt NYC on Sunday 11/4/2012
Brought to you by the CGD Center for MS at The Mount Sinai Medical Center.
http://www.mountsinai.org/mscenter
- published: 12 Feb 2013
- views: 1326
2:28
Frexalimab in Multiple Sclerosis | NEJM
- Order: Reorder
- Duration: 2:28
- Uploaded Date: 15 Feb 2024
- views: 2251
For patients with relapsing multiple sclerosis, inhibition of CD40L with the monoclonal antibody frexalimab may be a viable therapeutic strategy.
Research fin...
For patients with relapsing multiple sclerosis, inhibition of CD40L with the monoclonal antibody frexalimab may be a viable therapeutic strategy.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: https://nej.md/4bExZHa
https://wn.com/Frexalimab_In_Multiple_Sclerosis_|_Nejm
For patients with relapsing multiple sclerosis, inhibition of CD40L with the monoclonal antibody frexalimab may be a viable therapeutic strategy.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: https://nej.md/4bExZHa
- published: 15 Feb 2024
- views: 2251
3:51
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
- Order: Reorder
- Duration: 3:51
- Uploaded Date: 23 Mar 2022
- views: 453
Previously, Bruton's tyrosine kinase inhibitors (BTKis) have primarily been used for the treatment of B-cell cancers to deplete B-cell proliferation. BTKis are ...
Previously, Bruton's tyrosine kinase inhibitors (BTKis) have primarily been used for the treatment of B-cell cancers to deplete B-cell proliferation. BTKis are currently being investigated as a novel disease modifying therapy for the treatment of MS. Rochelle Benoit, MS, Memorial University of Newfoundland, St. John's, Newfoundland, Canada, discusses the use of BTKis in MS and investigations into their impact in non-B cell populations, including monocytes, macrophages, and microglia. When human-derived macrophages were treated with evobrutinib and tolebrutinib, a significant decrease in proinflammatory cytokine release was observed. The same effect was not seen in mouse-derived macrophages, suggesting a possible species difference in the cellular role of BTKs. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
https://wn.com/Btk_Inhibitors_Investigating_Disease_Relevant_Mechanisms_In_Multiple_Sclerosis
Previously, Bruton's tyrosine kinase inhibitors (BTKis) have primarily been used for the treatment of B-cell cancers to deplete B-cell proliferation. BTKis are currently being investigated as a novel disease modifying therapy for the treatment of MS. Rochelle Benoit, MS, Memorial University of Newfoundland, St. John's, Newfoundland, Canada, discusses the use of BTKis in MS and investigations into their impact in non-B cell populations, including monocytes, macrophages, and microglia. When human-derived macrophages were treated with evobrutinib and tolebrutinib, a significant decrease in proinflammatory cytokine release was observed. The same effect was not seen in mouse-derived macrophages, suggesting a possible species difference in the cellular role of BTKs. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
- published: 23 Mar 2022
- views: 453
1:00:05
Intelligent Intervention Into Multiple Sclerosis With Next-Generation Therapies
- Order: Reorder
- Duration: 1:00:05
- Uploaded Date: 02 Jul 2020
- views: 2351
As scientists learn more about the underlying causes of multiple sclerosis (MS), they are developing intelligent interventions that slow or halt the progression...
As scientists learn more about the underlying causes of multiple sclerosis (MS), they are developing intelligent interventions that slow or halt the progression of the disease. In this Front Row lecture, Scripps Research Professor Hugh Rosen will share how he and his collaborators at Scripps Research created ozanimod (Zeposia), the first disease-altering MS therapy, recently approved in the United States and Europe. Luke Lairson, an associate professor at Scripps Research, will discuss how his research targeting another aspect of the disease is laying the groundwork for the next generation of MS therapies.
Presented: July 1, 2020
https://www.scripps.edu
Register for future Front Row lectures: https://frontrow.scripps.edu/
https://wn.com/Intelligent_Intervention_Into_Multiple_Sclerosis_With_Next_Generation_Therapies
As scientists learn more about the underlying causes of multiple sclerosis (MS), they are developing intelligent interventions that slow or halt the progression of the disease. In this Front Row lecture, Scripps Research Professor Hugh Rosen will share how he and his collaborators at Scripps Research created ozanimod (Zeposia), the first disease-altering MS therapy, recently approved in the United States and Europe. Luke Lairson, an associate professor at Scripps Research, will discuss how his research targeting another aspect of the disease is laying the groundwork for the next generation of MS therapies.
Presented: July 1, 2020
https://www.scripps.edu
Register for future Front Row lectures: https://frontrow.scripps.edu/
- published: 02 Jul 2020
- views: 2351
1:03
Future studies on aHSCT for multiple sclerosis
- Order: Reorder
- Duration: 1:03
- Uploaded Date: 20 Dec 2022
- views: 114
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and future studies to improve the use of autologous hematopoietic stem ce...
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and future studies to improve the use of autologous hematopoietic stem cell transplantation (aHSCT) for the treatment of multiple sclerosis (MS). A clinical trial comparing aHSCT versus the best available therapy is ongoing, and its results are highly awaited. Studies investigating the long-term survival after aHSCT will provide important data about the potential of aHSCT to avoid the switch to the progressive phase of the disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
https://wn.com/Future_Studies_On_Ahsct_For_Multiple_Sclerosis
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and future studies to improve the use of autologous hematopoietic stem cell transplantation (aHSCT) for the treatment of multiple sclerosis (MS). A clinical trial comparing aHSCT versus the best available therapy is ongoing, and its results are highly awaited. Studies investigating the long-term survival after aHSCT will provide important data about the potential of aHSCT to avoid the switch to the progressive phase of the disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
- published: 20 Dec 2022
- views: 114
3:37
Nestorone for multiple sclerosis
- Order: Reorder
- Duration: 3:37
- Uploaded Date: 29 Sep 2020
- views: 1466
Nestorone, created by the Population Council Center for Biomedical Research, has the potential to help remyelinate axons damaged as a result of Multiple Scleros...
Nestorone, created by the Population Council Center for Biomedical Research, has the potential to help remyelinate axons damaged as a result of Multiple Sclerosis.
━━━━━━━━━━━━━━━━━━━━
Additional Information
────────────────────────────
https://www.popcouncil.org/cbr
━━━━━━━━━━━━━━━━━━━━
Science Animated
────────────────────────────
http://www.sciani.com/
https://twitter.com/Sci_Ani
https://www.facebook.com/scianimation/
━━━━━━━━━━━━━━━━━━━━
#Nestorone
#MultipleSclerosis
#MS
━━━━━━━━━━━━━━━━━━━━
https://wn.com/Nestorone_For_Multiple_Sclerosis
Nestorone, created by the Population Council Center for Biomedical Research, has the potential to help remyelinate axons damaged as a result of Multiple Sclerosis.
━━━━━━━━━━━━━━━━━━━━
Additional Information
────────────────────────────
https://www.popcouncil.org/cbr
━━━━━━━━━━━━━━━━━━━━
Science Animated
────────────────────────────
http://www.sciani.com/
https://twitter.com/Sci_Ani
https://www.facebook.com/scianimation/
━━━━━━━━━━━━━━━━━━━━
#Nestorone
#MultipleSclerosis
#MS
━━━━━━━━━━━━━━━━━━━━
- published: 29 Sep 2020
- views: 1466
5:14
Role of Ozanimod in Multiple Sclerosis
- Order: Reorder
- Duration: 5:14
- Uploaded Date: 25 Aug 2020
- views: 2045
Sven Meuth, MD, PhD, describes the phase 3 clinical trials SUNBEAM and RADIANCE of ozanimod for multiple sclerosis.
Sven Meuth, MD, PhD, describes the phase 3 clinical trials SUNBEAM and RADIANCE of ozanimod for multiple sclerosis.
https://wn.com/Role_Of_Ozanimod_In_Multiple_Sclerosis
Sven Meuth, MD, PhD, describes the phase 3 clinical trials SUNBEAM and RADIANCE of ozanimod for multiple sclerosis.
- published: 25 Aug 2020
- views: 2045
19:26
Unveil the hidden truth: Milk sabotages remyelination
- Order: Reorder
- Duration: 19:26
- Uploaded Date: 24 Jun 2024
- views: 338
Milk, often portrayed as a staple of health, harbors a dark side. Disguised within those innocent glasses lies a concoction of proteins that can incite inflamma...
Milk, often portrayed as a staple of health, harbors a dark side. Disguised within those innocent glasses lies a concoction of proteins that can incite inflammation, hindering the miraculous process of remyelination.
In this dairy dilemma, the choice to transition to a dairy-free, vegan lifestyle emerges not just as a dietary shift but as a transformative step towards fostering remyelination and embracing a path of healing and empowerment.
The story of remyelination transcends mere physical recovery; it symbolizes a journey of resilience, hope, and the profound impact of conscious dietary choices on one's health and vitality. Through the prism of remyelination, the narrative evolves into a tale of transformation, illustrating the potential for healing and wholeness through mindful decisions and unwavering belief in the body's innate capacity for renewal and restoration
Studies Cited:
The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/37492579/
Antibody cross-reactivity between casein and myelin-associated glycoprotein results in central nervous system demyelination
https://www.pnas.org/doi/10.1073/pnas.2117034119
Research Advances in the Analysis of Estrogenic Endocrine Disrupting Compounds in Milk and Dairy Products
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563511/
Hormones in Dairy Foods and Their Impact on Public Health - A Narrative Review Article
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524299/
Cow's milk protein can trigger inflammation in multiple sclerosis sufferers
https://www.news-medical.net/news/20220301/Cows-milk-protein-can-trigger-inflammation-in-multiple-sclerosis-sufferers.aspx
The extracellular region of bovine milk butyrophilin exhibits closer structural similarity to human myelin oligodendrocyte glycoprotein than to immunological BTN family receptors
https://pubmed.ncbi.nlm.nih.gov/34342946/
🥛🧠
#DairyDilemma
#RemyelinationRevolution
#remyelination
#MSRecovery
#Diet
#MS
#RestoringMyelin
#FightMS
#RegainAbilities
#Remyelinate
#Lifestyle
https://wn.com/Unveil_The_Hidden_Truth_Milk_Sabotages_Remyelination
Milk, often portrayed as a staple of health, harbors a dark side. Disguised within those innocent glasses lies a concoction of proteins that can incite inflammation, hindering the miraculous process of remyelination.
In this dairy dilemma, the choice to transition to a dairy-free, vegan lifestyle emerges not just as a dietary shift but as a transformative step towards fostering remyelination and embracing a path of healing and empowerment.
The story of remyelination transcends mere physical recovery; it symbolizes a journey of resilience, hope, and the profound impact of conscious dietary choices on one's health and vitality. Through the prism of remyelination, the narrative evolves into a tale of transformation, illustrating the potential for healing and wholeness through mindful decisions and unwavering belief in the body's innate capacity for renewal and restoration
Studies Cited:
The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/37492579/
Antibody cross-reactivity between casein and myelin-associated glycoprotein results in central nervous system demyelination
https://www.pnas.org/doi/10.1073/pnas.2117034119
Research Advances in the Analysis of Estrogenic Endocrine Disrupting Compounds in Milk and Dairy Products
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563511/
Hormones in Dairy Foods and Their Impact on Public Health - A Narrative Review Article
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524299/
Cow's milk protein can trigger inflammation in multiple sclerosis sufferers
https://www.news-medical.net/news/20220301/Cows-milk-protein-can-trigger-inflammation-in-multiple-sclerosis-sufferers.aspx
The extracellular region of bovine milk butyrophilin exhibits closer structural similarity to human myelin oligodendrocyte glycoprotein than to immunological BTN family receptors
https://pubmed.ncbi.nlm.nih.gov/34342946/
🥛🧠
#DairyDilemma
#RemyelinationRevolution
#remyelination
#MSRecovery
#Diet
#MS
#RestoringMyelin
#FightMS
#RegainAbilities
#Remyelinate
#Lifestyle
- published: 24 Jun 2024
- views: 338
5:18
New Studies Help Momentum Move Forward in Multiple Sclerosis Care
- Order: Reorder
- Duration: 5:18
- Uploaded Date: 20 Sep 2016
- views: 147
There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, an...
There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, and very early signs of hope for secondary progressive. As a result there was plenty of optimism at ECTRIMS as it left London and prepared for Paris next year.
https://wn.com/New_Studies_Help_Momentum_Move_Forward_In_Multiple_Sclerosis_Care
There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, and very early signs of hope for secondary progressive. As a result there was plenty of optimism at ECTRIMS as it left London and prepared for Paris next year.
- published: 20 Sep 2016
- views: 147
55:58
Research in Multiple Sclerosis | Webinar
Board Chair David W. Dodick, MD, FAAN hosted an informative discussion with Scientific Adv...
published: 08 Dec 2021
Research in Multiple Sclerosis | Webinar
Research in Multiple Sclerosis | Webinar
- Report rights infringement
- published: 08 Dec 2021
- views: 1559
Board Chair David W. Dodick, MD, FAAN hosted an informative discussion with Scientific Advisory Board Member Raymond Roos, MD, FAAN, about research in multiple sclerosis and what’s giving hope to those living with the disease. They discussed what is currently known about multiple sclerosis and what we need to learn to improve diagnosis and treatment. Audience members also had a chance to ask questions related to risk factors, modifying therapies, and research developments for multiple sclerosis.
For more information and resources visit our website at https://www.americanbrainfoundation.org/
Join our community:
Facebook: https://www.facebook.com/AmericanBrainFoundation/
Instagram: https://www.instagram.com/americanbrainfoundation/
Twitter: https://twitter.com/abfbrain
LinkedIn: https://www.linkedin.com/company/american-brain-foundation/
24:46
Research in MS: Can the Course be Modified? 2012 - by Patrizia Casaccia, MD
Presented at Changing the Future: New Trends in MS and Research, held at the Grand Hyatt N...
published: 12 Feb 2013
Research in MS: Can the Course be Modified? 2012 - by Patrizia Casaccia, MD
Research in MS: Can the Course be Modified? 2012 - by Patrizia Casaccia, MD
- Report rights infringement
- published: 12 Feb 2013
- views: 1326
Presented at Changing the Future: New Trends in MS and Research, held at the Grand Hyatt NYC on Sunday 11/4/2012
Brought to you by the CGD Center for MS at The Mount Sinai Medical Center.
http://www.mountsinai.org/mscenter
2:28
Frexalimab in Multiple Sclerosis | NEJM
For patients with relapsing multiple sclerosis, inhibition of CD40L with the monoclonal an...
published: 15 Feb 2024
Frexalimab in Multiple Sclerosis | NEJM
Frexalimab in Multiple Sclerosis | NEJM
- Report rights infringement
- published: 15 Feb 2024
- views: 2251
For patients with relapsing multiple sclerosis, inhibition of CD40L with the monoclonal antibody frexalimab may be a viable therapeutic strategy.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: https://nej.md/4bExZHa
3:51
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
Previously, Bruton's tyrosine kinase inhibitors (BTKis) have primarily been used for the t...
published: 23 Mar 2022
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
- Report rights infringement
- published: 23 Mar 2022
- views: 453
Previously, Bruton's tyrosine kinase inhibitors (BTKis) have primarily been used for the treatment of B-cell cancers to deplete B-cell proliferation. BTKis are currently being investigated as a novel disease modifying therapy for the treatment of MS. Rochelle Benoit, MS, Memorial University of Newfoundland, St. John's, Newfoundland, Canada, discusses the use of BTKis in MS and investigations into their impact in non-B cell populations, including monocytes, macrophages, and microglia. When human-derived macrophages were treated with evobrutinib and tolebrutinib, a significant decrease in proinflammatory cytokine release was observed. The same effect was not seen in mouse-derived macrophages, suggesting a possible species difference in the cellular role of BTKs. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
1:00:05
Intelligent Intervention Into Multiple Sclerosis With Next-Generation Therapies
As scientists learn more about the underlying causes of multiple sclerosis (MS), they are ...
published: 02 Jul 2020
Intelligent Intervention Into Multiple Sclerosis With Next-Generation Therapies
Intelligent Intervention Into Multiple Sclerosis With Next-Generation Therapies
- Report rights infringement
- published: 02 Jul 2020
- views: 2351
As scientists learn more about the underlying causes of multiple sclerosis (MS), they are developing intelligent interventions that slow or halt the progression of the disease. In this Front Row lecture, Scripps Research Professor Hugh Rosen will share how he and his collaborators at Scripps Research created ozanimod (Zeposia), the first disease-altering MS therapy, recently approved in the United States and Europe. Luke Lairson, an associate professor at Scripps Research, will discuss how his research targeting another aspect of the disease is laying the groundwork for the next generation of MS therapies.
Presented: July 1, 2020
https://www.scripps.edu
Register for future Front Row lectures: https://frontrow.scripps.edu/
1:03
Future studies on aHSCT for multiple sclerosis
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and...
published: 20 Dec 2022
Future studies on aHSCT for multiple sclerosis
Future studies on aHSCT for multiple sclerosis
- Report rights infringement
- published: 20 Dec 2022
- views: 114
Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and future studies to improve the use of autologous hematopoietic stem cell transplantation (aHSCT) for the treatment of multiple sclerosis (MS). A clinical trial comparing aHSCT versus the best available therapy is ongoing, and its results are highly awaited. Studies investigating the long-term survival after aHSCT will provide important data about the potential of aHSCT to avoid the switch to the progressive phase of the disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
3:37
Nestorone for multiple sclerosis
Nestorone, created by the Population Council Center for Biomedical Research, has the poten...
published: 29 Sep 2020
Nestorone for multiple sclerosis
Nestorone for multiple sclerosis
- Report rights infringement
- published: 29 Sep 2020
- views: 1466
Nestorone, created by the Population Council Center for Biomedical Research, has the potential to help remyelinate axons damaged as a result of Multiple Sclerosis.
━━━━━━━━━━━━━━━━━━━━
Additional Information
────────────────────────────
https://www.popcouncil.org/cbr
━━━━━━━━━━━━━━━━━━━━
Science Animated
────────────────────────────
http://www.sciani.com/
https://twitter.com/Sci_Ani
https://www.facebook.com/scianimation/
━━━━━━━━━━━━━━━━━━━━
#Nestorone
#MultipleSclerosis
#MS
━━━━━━━━━━━━━━━━━━━━
5:14
Role of Ozanimod in Multiple Sclerosis
Sven Meuth, MD, PhD, describes the phase 3 clinical trials SUNBEAM and RADIANCE of ozanimo...
published: 25 Aug 2020
Role of Ozanimod in Multiple Sclerosis
Role of Ozanimod in Multiple Sclerosis
- Report rights infringement
- published: 25 Aug 2020
- views: 2045
Sven Meuth, MD, PhD, describes the phase 3 clinical trials SUNBEAM and RADIANCE of ozanimod for multiple sclerosis.
19:26
Unveil the hidden truth: Milk sabotages remyelination
Milk, often portrayed as a staple of health, harbors a dark side. Disguised within those i...
published: 24 Jun 2024
Unveil the hidden truth: Milk sabotages remyelination
Unveil the hidden truth: Milk sabotages remyelination
- Report rights infringement
- published: 24 Jun 2024
- views: 338
Milk, often portrayed as a staple of health, harbors a dark side. Disguised within those innocent glasses lies a concoction of proteins that can incite inflammation, hindering the miraculous process of remyelination.
In this dairy dilemma, the choice to transition to a dairy-free, vegan lifestyle emerges not just as a dietary shift but as a transformative step towards fostering remyelination and embracing a path of healing and empowerment.
The story of remyelination transcends mere physical recovery; it symbolizes a journey of resilience, hope, and the profound impact of conscious dietary choices on one's health and vitality. Through the prism of remyelination, the narrative evolves into a tale of transformation, illustrating the potential for healing and wholeness through mindful decisions and unwavering belief in the body's innate capacity for renewal and restoration
Studies Cited:
The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/37492579/
Antibody cross-reactivity between casein and myelin-associated glycoprotein results in central nervous system demyelination
https://www.pnas.org/doi/10.1073/pnas.2117034119
Research Advances in the Analysis of Estrogenic Endocrine Disrupting Compounds in Milk and Dairy Products
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563511/
Hormones in Dairy Foods and Their Impact on Public Health - A Narrative Review Article
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524299/
Cow's milk protein can trigger inflammation in multiple sclerosis sufferers
https://www.news-medical.net/news/20220301/Cows-milk-protein-can-trigger-inflammation-in-multiple-sclerosis-sufferers.aspx
The extracellular region of bovine milk butyrophilin exhibits closer structural similarity to human myelin oligodendrocyte glycoprotein than to immunological BTN family receptors
https://pubmed.ncbi.nlm.nih.gov/34342946/
🥛🧠
#DairyDilemma
#RemyelinationRevolution
#remyelination
#MSRecovery
#Diet
#MS
#RestoringMyelin
#FightMS
#RegainAbilities
#Remyelinate
#Lifestyle
5:18
New Studies Help Momentum Move Forward in Multiple Sclerosis Care
There are now more than a dozen medications approved for the treatment of relapsing multip...
published: 20 Sep 2016
New Studies Help Momentum Move Forward in Multiple Sclerosis Care
New Studies Help Momentum Move Forward in Multiple Sclerosis Care
- Report rights infringement
- published: 20 Sep 2016
- views: 147
There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, and very early signs of hope for secondary progressive. As a result there was plenty of optimism at ECTRIMS as it left London and prepared for Paris next year.
Multiple sclerosis
Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often occur, especially as the disease advances.
While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as infections. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.
This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/Multiple_sclerosis
Research in Multiple Sclerosis | Webinar...
Research in MS: Can the Course be Modified? 2012 -...
Frexalimab in Multiple Sclerosis | NEJM...
BTK inhibitors: Investigating disease relevant mec...
Intelligent Intervention Into Multiple Sclerosis W...
Future studies on aHSCT for multiple sclerosis...
Nestorone for multiple sclerosis...
Role of Ozanimod in Multiple Sclerosis...
Unveil the hidden truth: Milk sabotages remyelinat...
